Fimea

The summaries of product characteristics (SPC) contain the information relevant to the use of the medicinal products and of importance to health care professionals. The SPCs are published in Finnish; the use of Finnish key words in the search fields is therefore recommended.

Some of the medicinal products contain a condition relevant to the prescribing of the product and not always found in the SPC. The conditions for prescribing and the products covered by this condition are found in the FimeaWeb search.

The SPCs processed as part of the EU centralised marketing authorisation procedure are published by the European Medicines Agency, EMA. Fimea's service contains links to the documents on medicinal products (EPAR PI) on the EMA website. Drugs belonging to the centralised authorisation procedure can be searched in Fimea's service by using an alphabetical list or by entering the product name or ATC code.

The material being published is not necessarily complete or up-to-date due to the technical quality of files submitted to the Finnish Medicines Agency Fimea or earlier to the National Agency for Medicines and the delays in delivery. For this reason, Fimea cannot guarantee that the document on the Internet fully complies with the summary of product characteristics and package leaflet officially approved by a desicion for a marketing authorisation. Only the hard copies of the SPCs and the PLs, which are in accordance with the marketing authorisation, are conclusive.

Search with the first character of the name of the medicinal product: u

Summaries of Product Characteristics 1 - 28 of 28

Package
leaflet

Status for
supply

Name of the medicinal product

Resepti

Ubistesin 40 mg-ml + 5 mikrog-ml injektioneste, liuos, SPC 2023-11-01

Resepti

Ubistesin Forte 40 mg-ml + 10 mikrog-ml injektioneste, liuos, SPC 2023-11-01

Resepti

Ubistesin Mild 40 mg-ml + 2,5 mikrog-ml injektioneste, liuos, SPC 2023-11-01

European Medicines Agency's website:
Ucedane - EMA: EPAR PI
Finnish Swedish